没有疾病的世界Quickfire挑战

Maryland-based Glyscend, Inc., led by Ashish Nimgaonkar, M.D., Co-founder and CEO, is developing transformative therapies for metabolic diseases (such as type 2 diabetes and obesity) by reducing the concept of bariatric (gastric bypass) surgery into a pill. While type 2 diabetes has traditionally been treated with oral and injectable drugs, these therapies compound over a patient’s lifetime causing weight gain and potentially leading to greater insulin resistance. Bariatric surgery has been shown to have a profound beneficial effect, not only on obesity but also on type 2 diabetes independent of weight loss. Based on the insights from these surgeries, Glyscend is developing the first orally administered intestinal barrier which mimics the intestinal bypass portion of bariatric surgery, thus providing the therapeutic benefits of this surgery in a pill form.

Celi Kaplan领导的加利福尼亚州的神经浪费是在一项任务中转变诊断和预防因阿尔茨海默氏症等内存损失和相关疾病。该公司的产品是Imprint™检查，这是一个五分钟的测试，它使用眼跟踪技术来评估症状出现之前的认知下降。早期诊断记忆损失对于预防认知下降至关重要，并且该测试是唯一可以在它开始之前预测内存损耗的工具。此外，Neurotrack提供了一种认知健康计划，为用户提供工具和建议，以使生活方式改变科学证明，以降低阿尔茨海默氏症等认知下降和疾病的风险。

RMIT大学的微/纳米医科研究中心由Leslie Yeo，Ph.D，开发了由便携式手持式个性化雾化平台组成的核心技术，可通过吸入肺部渗透到肺部的药物。该技术不仅提供无针对非和大型分子治疗的无针给药和机会，而且还有机会直接针对肺部靶向，这使其对于靶向肺癌（包括肺癌）非常有吸引力是代表批判性未满足的特定区域。